Transaction #19310 · Form 4 · 0001683168-25-009113
PharmaCyte Biotech, Inc. · Stock award · Stock Option (Right to Buy)
PharmaCyte Biotech, Inc. · Transacted April 25, 2025 · Filed December 12, 2025
What does this filing report?
An SEC Form 4 filing for PharmaCyte Biotech, Inc. records a stock award involving Stock Option (Right to Buy) on April 25, 2025. The reported quantity was 63,233. The filing date is December 12, 2025. This is one transaction record; amounts are not allocated among any joint reporting owners.
The acquisition category describes how securities were received. It does not by itself establish a cash purchase of common stock. Read the transaction code definitionsand the original filing before interpreting the amounts.
Transaction details
- Company
- PharmaCyte Biotech, Inc.
- Company CIK
- 0001157075
- Security type
- Derivative
- Acquisition type
- Stock award · Code A
- Quantity acquired
- 63,233
- Reported price
- 0
- Reference value
- 0
- Currency
- Currency not specified
- Ownership
- Direct
- Holdings after transaction
- 63,233
- Ownership description
- Not reported
- SEC acceptance time
- Dec 12, 2025, 5:07 PM EST
- 10b5-1 indication
- Not indicated
Reference value is reported quantity × reported price. It is not a confirmed cash payment or an estimate of a derivative's economic value. A missing currency is not assumed to be USD.
Reporting owners
- SCHECHTER JONATHAN ↗
Director
CIK 0001619259
These are the reporting owners named in the filing. Quantities and amounts are not allocated among co-reporters. Roles reflect this filing, not a current profile.
Company listings
This transaction is not mapped to a specific company listing.
Derivative terms
- Underlying security
- Common Stock
- Underlying quantity
- 63,233
- Conversion / exercise price
- 1.22
- Exercise date
- Not reported
- Expiration date
- April 24, 2035
Filing footnotes & remarks
- F1
- Represents shares withheld by the Issuer to satisfy the tax liability upon vesting of restricted stock units and does not constitute an actual sale or other open-market transaction.
- F2
- The options shall vest in full on the date of the Issuer's next annual meeting of stockholders, subject to the continued service of Mr. Schechter. This transaction is late due to an inadvertent administrative error and not any error of Mr. Schechter.
Remarks
Exhibit 24.1 - Power of Attorney
Footnotes are reproduced as plain text from the current source filing. For the full context, read the original SEC filing.
This record was updated Eastern Time. This is the stored record update time, not the transaction date. Report a correction.